Floatz Rating
CC46/100
Confidence
Indicative
Sponsor
Beth Israel Deaconess Medical Center
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00325013CT.gov Evaluation of DHA for the Treatment of PSC | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Docosahexaenoic Acid (this asset) | Beth Israel Deaconess Medical Center | P1 | CC · 46 |
| Infliximab | Therakos LLC | P2 | B |
| Vedolizumab | Therakos LLC | P2 | B |
| Mercaptopurine Anhydrous | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| VITPSO | Therakos LLC | P2 | CCC |
| Adalimumab | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Mesalamine | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
| Azathioprine | Therakos LLC | P2 | CCC |
| Tacrolimus | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | CCC |
+3 more in the Colitis cohort
Other indications for Docosahexaenoic Acid
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Obesity Disorder | — | P4 | BBB · 72 |
| Fibrotic Liver Disease | — | P3 | B · 62 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P3 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Docosahexaenoic Acid in Colitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/docosahexaenoic-acid-colitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →